Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

• Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

• Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

• Top Pre-Market Movers: Identify early winners poised for a strong market opening.

• Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

• FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 09:00 AM ET – FOMC Member Bowman Speaks

✓ 10:00 AM ET – Michigan 1-Year Inflation Expectations (May)

✓ 10:00 AM ET – Michigan 5-Year Inflation Expectations (May)

✓ 10:00 AM ET – Michigan Consumer Expectations (May)

✓ 10:00 AM ET – Michigan Consumer Sentiment (May)

✓ 12:00 PM ET – WASDE Report

PREMARKET SNAPSHOT 📈

Stock futures are pointing to a flat open with the Dow Jones leading the way with a modest gain of nearly 1%.

SECTOR SNAPSHOT ✨

Most sectors edged up in today's mixed market; Real Estate surged 2.31%, while Tech dipped 0.25%.

Unusual Volume

📈 Reborn Coffee Inc (REBN) jumped 84.39% to $3.19 on a whopping 109.96 million shares traded after it announced a significant expansion into the China market through a strategic Master License Agreement with IAID Co., Ltd.

📈 Investors went wild, sending Fuelcell Energy Inc (FCEL) stock declining -3.52% to $0.76 on a massive volume of 84.39 million shares.

📈 Abnormal activity shook Uber Technologies Inc (UBER), pushing it down -5.72% to $66.40 on a whopping 84.22 million shares traded after announcing results for first quarter 2024.

📈 Safe and Green Development Corp (SGD) stock recently closed 58.81% upper at $0.62 on substantial volume of 70.08 million shares. This unusual activity came after the company announced its partnership with Affiliated Services Group (ASG) to offer mortgage banking related services on its innovative Xene platform across 49 states in the U.S.

📈 Luminar Technologies Inc (LAZR) increase by 18.79% in a single trading session, with abnormally high trading volume of 61.55 million shares. The company provided its quarterly business update and financial results for the first quarter of 2024.

Premarket Movers

Novavax, Inc. (NVAX) experiences a substantial 115.44% surge in pre-market trading after announcing a co-exclusive licensing agreement with Sanofi.

AEye, Inc. (LIDR) sees a significant 35.59% increase, reaching a pre-market price of $1.60 after announcing partnership with leading automotive electronics and vision solutions provider, LITEON.

SoundHound AI, Inc. (SOUN) demonstrates a noteworthy 14.11% surge, with a pre-market price of $5.42 after reporting 73% Q1 revenue growth to $11.6 million.

Important FDA 

Recently Announced

April 29th, 2024, marks a pivotal moment in Pfizer Inc.'s (PFE) journey as the FDA grants full approval for TIVDAK, a breakthrough in treating recurrent or metastatic cervical cancer. This decision highlights Tivdak's efficacy and safety, providing a beacon of hope for patients post-initial therapy, offering potential for improved outcomes.

On April 30th, 2024, Neurocrine Biosciences Inc. (NBIX) achieves a significant milestone with the FDA's approval of INGREZZA's oral granules formulation. This innovative drug delivery system signals a new chapter in managing tardive dyskinesia and chorea linked to Huntington's disease.

April 30th, 2024, emerges as a historic date for X4 Pharmaceuticals, Inc (XFOR), as the FDA greenlights Mavorixafor, bringing hope to individuals aged 12 and older grappling with WHIM syndrome. This approval not only confirms Mavorixafor's effectiveness and safety but also marks a crucial advancement in treating this rare and challenging condition.

Upcoming Announcements

The anticipation surrounding Moderna's (MRNA) pivotal moment on May 12th, 2024, is palpable. As the FDA's decision on mRNA-1345, their innovative RSV vaccine, looms closer, stakeholders are holding their breath. If the outcome aligns with expectations, it could signify a significant advancement in the fight against respiratory syncytial virus, promising a safer and more efficient defense against this widespread threat.

May 13th, 2024, holds immense significance for Dynavax Technologies Corp. (DVAX) as they await the FDA's ruling on HEPLISAV-B, a vaccine with potential expanded usage among adults undergoing hemodialysis. With anticipation mounting among stakeholders as the date approaches, there's a sense of anticipation for a potential breakthrough that could elevate the standard of care for this vulnerable patient group.

On May 14th, 2024, attention shifts to Ascendis Pharma A/S (ASND) as they await the FDA's decision on TransCon PTH. With the resubmitted NDA targeting the urgent needs of adult patients grappling with hypoparathyroidism, the outcome carries significant weight. A favorable verdict could signal a new chapter in treatment options, providing hope and relief for those burdened by this challenging condition.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.